Biofrontera Appeals PTAB, Seeks Cancellation of Dusa’s Patent
shot by IP News Shots / 5:22 pm on 21 October, 2021
Biofrontera AG has approached U.S.Patent Trial and Appeal Board (PTAB) for its petition to cancel a patent owned by Sun Pharmaceutical Industries Limited’s owned Dusa Pharmaceuticals, Inc. Both the companies have treatments for a pre-cancerous skin condition actinic keratosis. The plaintiff is claiming that the defendant is infringing the patent that covers “a common off-label use” of the therapy.
Industry: Pharmaceuticals | Type of IP: Litigations
Read more at Bloomberg Law